Q-omics provides the consensus-scored UBE2H profile across patient tissues and cancer cell-line models. UBE2H expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in PAAD. Among the 18 cancer types available for tumor–normal comparison, UBE2H is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, UBE2H RNA expression shows 19,782 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight PAAD, HNSC, and ACC as cancer lineages where UBE2H shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for UBE2H — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes UBE2H survival associations across molecular data types. UBE2H RNA expression shows survival associations in the most cancer types (24), followed by mutation status (1) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible UBE2H RNA expression–survival associations across cancer types. High UBE2H expression shows unfavorable associations in PAAD, HNSC, COAD, LUAD, MESO and UVM. The PAAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify PAAD as the clearest survival context for UBE2H RNA expression.
This table summarizes UBE2H tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for UBE2H. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. UBE2H shows higher tumor expression in HNSC, KIRP, LIHC, LUAD, BRCA and COAD. The HNSC box plot shows higher UBE2H RNA expression in tumor versus normal tissue (log2 FC = +0.919, t-test p < 0.001).
This table shows molecular features associated with UBE2H in patient tissues and cancer cell lines. In patient samples, UBE2H shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, UBE2H RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and CNS.
